Warfarin Use and Increased Mortality in End-Stage Renal Disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Controversy exists regarding the benefits and risks of warfarin therapy in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. In this study, we assessed mortality and cardiovascular outcomes associated with warfarin treatment in patients with stages 3-5 CKD and ESRD admitted to the University of California-Irvine Medical Center.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am. J. Nephrol.

Title: American journal of nephrology

Publisher: S. Karger AG

ISSN (Electronic): 1421-9670

ISSN (Print): 0250-8095

Publication date (Electronic): 2017

Volume: 46

Issue: 4

Affiliations

[1 ] School of Medicine, University of California, Irvine, CA, USA.

Article

Publisher Item ID: 000481207 Mid ID: NIHMS911005

DOI: 10.1159/000481207

PMC ID: 5657430

PubMed ID: 28910806

SO-VID: 9872e4b2-1c0f-44c8-b0ef-41187fc87883

History

Keywords: Mortality,Stroke,Warfarin,Bleeding,Chronic kidney disease

Data availability:

Keywords: Mortality, Stroke, Warfarin, Bleeding, Chronic kidney disease

Comments

Comment on this article

scite_

Cited by 7

See all cited by

- Version 1
- Version 1

Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

Submit here before September 30, 2024